54385-49-8

Basic information

• Product Name: 3-amino-1H-pyrazole-4,5-dicarbonitrile
• Synonyms: 3-amino-1H-pyrazole-4,5-dicarbonitrile;1H-Pyrazole-3,4-dicarbonitrile, 5-amino-;3-Aminopyrazole-4,5-dicarbonitrile;5-amino-1H-pyrazole-3,4-dicarbonitrile
• CAS NO: 54385-49-8
• Molecular Formula: C₅H₃N₅
• Molecular Weight: 133.11
• Product Categories: API intermediates
• Mol File: 54385-49-8.mol

Chemical Properties

• Boiling Point: 626.742 °C at 760 mmHg
• Flash Point: 332.842 °C
• Appearance: /
• Density: 1.549 g/cm³
• Vapor Pressure: 1.27E-15mmHg at 25°C
• Refractive Index: 1.647
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 7.10±0.50(Predicted)
• CAS DataBase Reference: 3-amino-1H-pyrazole-4,5-dicarbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-amino-1H-pyrazole-4,5-dicarbonitrile(54385-49-8)
• EPA Substance Registry System: 3-amino-1H-pyrazole-4,5-dicarbonitrile(54385-49-8)

Safety Data

• Hazardous Substances Data: 54385-49-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-1H-pyrazole-4,5-dicarbonitrile serves as a crucial building block in the synthesis of a range of pharmaceutical drugs. Its role in drug development is significant due to its ability to contribute to the creation of new medicinal compounds.
Used in Organic Synthesis:
As a versatile intermediate, 3-Amino-1H-pyrazole-4,5-dicarbonitrile is utilized in organic synthesis for the development of novel materials and catalysts, showcasing its broad applicability in chemical research and industry.
Used in Biological and Pharmacological Research:
3-Amino-1H-pyrazole-4,5-dicarbonitrile has been the subject of studies exploring its potential biological and pharmacological properties. It has demonstrated promise in antiparasitic, anti-inflammatory, and antiviral activities, making it a valuable candidate for further research and potential therapeutic applications.

InChI:InChI=1/C5H3N5/c6-1-3-4(2-7)9-10-5(3)8/h(H3,8,9,10)

Upstream product

• 870-46-2 t-butoxycarbonylhydrazine 
• 670-54-2 ethenetetracarbonitrile 
• 5745-84-6 5-amino-3,4-dicyano-pyrazole-1-carboxylic acid amide 

Downstream Products

• 6826-96-6 4-amino-3-cyano-pyrazolo<3,4-d>pyrimidine 
• 55559-54-1 1-(β-D-Ribofuranosyl)-3-thiocarbamoyl-4-aminopyrazolo<3,4-d>pyrimidine 
• 82859-58-3 3-Cyano-4-mercaptopyrazolo<3,4-d>pyrimidine 
• 90213-35-7 3-Thiocarbamoyl-4-methylmercaptopyrazolo<3,4-d>pyrimidine 
• 82859-59-4 4-Hydrazinopyrazolo<3,4-d>pyrimidine-3-carboxylic Acid Iminohydrazide 
• 80117-81-3 1-(β-D-Ribofuranosyl)-3-cyano-4-methylmercaptopyrazolo<3,4-d>pyrimidine 
• 80117-82-4 1-(β-D-Ribofuranosyl)-3-thiocarbamoyl-4-methylmercaptopyrazolo<3,4-d>parimidine 
• 90318-68-6 1-(2',3',5'-Tri-O-acetyl-β-D-ribofuranosyl)-3-thiocarbamoyl-4-methylmercaptopyrazolo<3,4-d>pyrimidine 
• 80117-80-2 1-(2',3',5'-Tri-O-acetyl-β-D-ribofuranosyl)-3-cyano-4-methylmercaptopyrazolo<3,4-d>pyrimidine 
• 90213-39-1 2-(2',3',5'-Tri-O-acetyl-β-D-ribofuranosyl)-3-cyano-4-methylmercaptopyrazolo<3,4-d>pyrimidine 
• 80117-79-9 3-Cyano-4-methylmercaptopyrazolo<3,4-d>pyrimidine 

Relevant articles and documents

ATG7 INHIBITORS AND THE USES THEREOF

Disclosed are chemical entities which are compounds of formula (I) : or a pharmaceutically acceptable salt thereof, wherein R1, R2, and Ra have the values described herein. Chemical entities according to the disclosure can be useful as inhibitors of ATG7. Further provided are pharmaceutical compositions comprising a chemical entity of the disclosure and methods of using the compositions in the treatment of cancer.

4-amino-3-(imidazolylmethyl)-Pyrazolopyridine [3, 4-D] pyrimidinecarboxylic

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 4-amino-3-imidazoyl-pyrazolo[3,4-d]pyrimidine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.

6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof

Novel 6-heterocyclyl-pyrazolo[3,4-d]pyrimidin-4-ones, useful in treating cardiovascular disease, are prepared by reacting a 5-amino-1H-pyrazole-4-carboxamide with heterocyclylcarboxaldehyde or by reacting a 5-amino-1H-pyrazole-4-carbonitrile with a heterocyclylcarboxamidine, followed by diazotization and hydrolysis of the resulting 4-amino-6-heterocyclyl-pyrazolo[3,4-d]pyrimidine.